Oslo, Norway, February 5, 2025 - Lytix Biopharma AS ("Lytix" or the "Company")
will release its fourth quarter 2025 financial results and publish its second
half 2025 financial report on Thursday, February 12, 2025.

Join us for a live webcast presentation featuring CEO Øystein Rekdal and CFO
Gjest Breistein, where they will discuss the Q4 results and provide key
insights. 

Date: Thursday, February 12, 2025
Time: 10:00 AM CET

Q&A Session:
We welcome your questions in advance. Please send them to
post@lytixbiopharma.com, and they will be addressed during the Q&A session
following the presentation.

Webcast Details:
The presentation and Q&A session will be conducted in English. You can view the
live event by registering here: https://qcnl.tv/p/Bs5cUOyZOtu__8Vd3OK5_Q 

Missed the Live Session?
A recording of the presentation will be available shortly after the event on our
financial reports page: https://www.lytixbiopharma.com/financial-reports 

For more information, please contact: 
Gjest Breistein, CFO 
+47 952 60 512
gjest.breistein@lytixbiopharma.com

About Lytix:
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly differentiated oncolytic molecule platform based on world-leading
research in host-defense peptide-derived molecules. Lytix Biopharma's lead
product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule
representing a new approach to maintaining durable anti-cancer immunity. Lytix
Biopharma has a pipeline of molecules that work across multiple cancer
indications and treatment settings, both as mono- and combination therapy. Lytix
is listed on Euronext Growth Oslo under the ticker LYTIX.
For more information, visit www.lytixbiopharma.com.